Comparative Pharmacology
Head-to-head clinical analysis: ADCIRCA versus SILDENAFIL CITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADCIRCA versus SILDENAFIL CITRATE.
ADCIRCA vs SILDENAFIL CITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase-5 (PDE5) inhibitor; increases cGMP in pulmonary vascular smooth muscle, leading to vasodilation.
Sildenafil citrate inhibits phosphodiesterase type 5 (PDE5) in the corpus cavernosum, increasing cGMP levels and enhancing nitric oxide-mediated smooth muscle relaxation, leading to penile erection. It also inhibits PDE5 in pulmonary vasculature, causing vasodilation and reducing pulmonary artery pressure.
10 mg orally three times daily.
50 mg orally as needed approximately 1 hour before sexual activity; range 25-100 mg based on efficacy and tolerability; maximum dosing frequency once per day.
None Documented
None Documented
Terminal half-life: 10–15 hours in healthy adults; prolonged in hepatic impairment (Child-Pugh B/C: up to 30 hours); clinical context: supports twice-daily dosing
Terminal elimination half-life 3-5 hours; clinical effect duration shorter due to distribution.
Renal: ~70% (metabolites and unchanged drug), Fecal: ~20%, Biliary: minor
Approximately 80% fecal, 13% renal as metabolites; <1% unchanged in urine.
Category C
Category A/B
PDE5 Inhibitor
PDE5 Inhibitor